ArticleBMJ (Clinical research ed.)2023
Prevalence, awareness, treatment, and control of hypertension in China, 2004-18: findings from six rounds of a national survey.
Article in BMJ (Clinical research ed.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 215 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
215 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Prevalence and treatment and control rates of hypertension among Chinese adults from 2016 to 2022: a meta-analysis.BMC public health · 2026Pooled it
- National, regional, and provincial prevalence of glaucoma in China in 2020: an updated systematic review and modelling analysis.Journal of global health · 2025Pooled it
- Community-integrated noncommunicable disease service models: lessons from China.Journal of global health · 2025Pooled it
- An RCT META analysis based on the efficacy of Tai Chi exercise therapy on blood pressure and blood lipids in patients with essential hypertension.Frontiers in cardiovascular medicine · 2025Pooled it
- Motivational interviewing intervention for the management of hypertension: a meta-analysis.Frontiers in cardiovascular medicine · 2024Pooled it
- Prevalence of hypertension and related risk factors in older Chinese population: a meta-analysis.Frontiers in public health · 2024Pooled it
- [Effects of a lung recruitment maneuver combined with individualized positive end-expiratory pressure on postoperative pulmonary complications and perioperative hemodynamics in hypertensive patients undergoing pulmonary resection].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026Trial
- Effect of a Mobile Health Intervention in the Management of Hypertension: Open-Label Cluster-Randomized Trial.JMIR mHealth and uHealth · 2025Trial
- A village doctor-led mobile health intervention for cardiovascular risk reduction in rural China: cluster randomised controlled trial.BMJ (Clinical research ed.) · 2025Trial
- Effectiveness of a Patient-Family Carer Partnership Intervention on Blood Pressure Control for People with Hypertension in Rural Communities: A Randomised Controlled Trial.Journal of nursing management · 2024Trial
- Hypertension management in transition: gains, gaps, and growing challenges in a high-altitude multi-ethnic region of China (2019-2024).Annals of medicine · 2026Article
- Effectiveness of a Primary-Care-Centered Integrated Care Intervention for Stratified Cardiovascular Risk Control in China: Study Protocol for a Pragmatic Cluster Randomized Controlled Trial.Health care science · 2026Article
- Association between serum zinc levels and new-onset hypertension: A 5-year retrospective cohort study.Medicine · 2026Article
- Plan-related inequalities in costs, disease progression and mortality among hypertensive patients in China.Nature communications · 2026Article
- Review
- Standardized chronic disease management reduces comorbidity risk in China.Nature communications · 2026Article
- Trends in Cardiovascular Diseases Burden in China, 1990-2023: A Global Burden of Disease Analysis.JACC. Asia · 2026Article
- From Descriptive Epidemiology to Precision Action: Translating GBD Insights Into Cardiovascular Prevention in China.JACC. Asia · 2026Article
- Trajectories of blood pressure and influencing factors across menopause: A longitudinal cohort study.American journal of preventive cardiology · 2026Article
- Association ofGenes · 2026Article
155 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
objectiveTo assess the recent trends in prevalence and management of hypertension in China, nationally and by population subgroups.
designSix rounds of a national survey, China.
settingChina Chronic Disease and Risk Factors Surveillance, 2004-18.
participants642 523 community dwelling adults aged 18-69 years (30 501 in 2004, 47 353 in 2007, 90 491 in 2010, 156 836 in 2013, 162 293 in 2015, and 155 049 in 2018).
main outcome measuresHypertension was defined as a blood pressure of ≥140/90 mm Hg or taking antihypertensive drugs. The main outcome measures were hypertension prevalence and proportion of people with hypertension who were aware of their hypertension, who were treated for hypertension, and whose blood pressure was controlled below 140/90 mm Hg.
resultsThe standardised prevalence of hypertension in adults aged 18-69 years in China increased from 20.8% (95% confidence interval 19.0% to 22.5%) in 2004 to 29.6% (27.8% to 31.3%) in 2010, then decreased to 24.7% (23.2% to 26.1%) in 2018. During 2010-18, the absolute annual decline in prevalence of hypertension among women was more than twice that among men (-0.83 percentage points (95% confidence interval -1.13 to -0.52)
conclusionsThe prevalence of hypertension in China has slightly declined since 2010, but treatment and control remain low. The findings highlight the need for improving detection and treatment of hypertension through the strengthening of primary care in China, especially in rural areas.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.